While there is some support for no treatment in GCK-related hyperglycemia and sulphonylureas for HNF1A-diabetes, overall there is limited evidence to guide the treatment in monogenic diabetes with most studies being non-randomized and small. This evidence concerns the gene GCK and Hyperglycemia.